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Endothelin (ET), a potent endothelium-derived vasoconstric-
tor peptide [1] contributes to the regulation of glomerular
function both through changes in hemodynamics and through
changes in glomerular configuration. Three structurally and
pharmacologically distinct isoforms of the peptide have been
identified with a molecular weight of 2.5 kDa, each consisting of
21 amino acids. These isopeptides share a common structure
with a hydrophobic C-terminal end and two disulfide bonds,
thus forming a hairpin loop at the amino terminus. ET-l differs
from ET-2 by only two amino acids, and from ET-3 by six
amino acids. Each ET isopeptide is encoded by separate genes
at distinct chromosomal loci [2].
All ETs are synthesized via proteolytical cleavage from
specific prohormones (Fig. 1). Prepro ETs are long polypeptide
chains consisting of ---203 amino acids [1] which exhibit specific
differences among the isopeptides. ET isopeptide precursors
are proteolytically cleaved by processing endopeptidases that
recognize paired basic amino acids (Arg-Arg or Lys-Arg) and
thus form pro or big ET. Pro ET-l is then converted to mature
ET-1 by cleavage of the Trp21-Va122 bond via a highly specific
endothelin-1-converting enzyme, which is a Phosphoramidon-
sensitive, membrane bound metalloprotease (Fig. 1) [3—5]. Pro
ET-3 is less susceptible to this protease, so that the presence of
other types of endothelin-converting enzyme are suspected [5].
ETs bind to two G—protein coupled receptors of —43 to —73
kD molecular weight [6—8], consisting of —415 to —427 amino
acids and having seven transmembrane domains [6, 7]. The
ETA receptor binds ET-l with 2- to 10-fold higher affinity than
ET-2 and> 100-fold higher affinity than ET-3 [6—9], whereas the
ETB receptor has similar affinities to all three peptides [7, 8].
Little is known about the fate of ET. ETs are either inacti-
vated by receptor internalization or by enzymatic cleavage of
the peptide prior to receptor coupling [10—13].
Renal synthesis of endothelins
Most renal cell types are capable of producing ETs: glomer-
ular endothelial cells [14], mesangial cells [15, 16], glomerular
epithelial cells [17—19], as well as renal tubular epithelial cells
[20]. Northern blotting techniques [1, 2, 21—28], RNase protec-
tion assays [29] and reverse transcription-polymerase chain
reaction (RT-PCR) techniques [30—32] have been successfully
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applied to precisely quantify the isopeptide synthesis in specific
regions of the kidney.
The kidney synthesizes both ET-1 and ET-3 [20]. In micro-
dissected rat kidney nephron segments ET-l mRNA can be
found in glomeruli and in inner medullary collecting ducts,
however, it is negligible in the cortical collecting duct, outer
medullary collecting duct, and undetectable in other nephron
segments (Fig. 2) [30, 31]. These findings correlate with immu-
noreactive ET-1 production in isolated cell culture as well as
nephron segment suspensions.
Synthesis of ET-2 in the kidney has not been clarified in
detail. ET-2 is expressed in human renal medulla, and renal
adenocarcinomas produce exceptionally high levels of ET-2
[33].
Immunoreactive ET-1 and ET-3 mRNA are abundantly ex-
pressed in distal nephrons [201. In microdissected rat nephrons
the following pattern for ET-3 can be found: outer medullary
collecting duct > proximal convoluted tubule > cortical col-
lecting duct > proximal straight tubule > glomerulus > vasa
recta bundle. Weak signals are shown in inner medullary
collecting duct > terminal inner rnedullary collecting duct >
medullary thick ascending limb> inner medullary thin limb and
arcuate artery (Fig. 2) (Terada Y, personal communication).
The kidney does not express exceptionally high levels of the
ET isopeptides compared to other organs [29], but the kidney is
distinguished from other organs by the unique co-localization
for ET-1 and ET-3 mRNA in the glomerulus. This finding might
enable the nephron to respond to both isopeptides although the
physiological relevance remains to be elucidated.
Renal physiologic actions of endothelins
ET-1 dose-dependently reduces RBF and GFR. Constriction
of the efferent and afferent arterioles accounts for the glomer-
ular effects through increase of RVR [35] and reduction of
glomerular renal plasma flow (QA) [36, 37]. ET-1 also contracts
mesangial cells, thus reducing glomerular filtration surface area
[38] and glomerular ultrafiltration coefficient (Kf) [39]. At low
concentrations ET reduces RBF and GFR but increases urinary
flow rate, urinary sodium excretion and osmolar clearance [40].
Increasing concentrations of ET reverse part of these physio-
logic effects. Concommitant with further reduction of RBF and
GFR, urinary flow rate falls and urinary sodium excretion as
well as urine osmolar clearance and osmolarity [37] is reduced.
The explanation for these effects is in part the dose-dependent
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capacity for tubular sodium reabsorption in the medullary thick
ascending limb of Henle' s loop as well as for water reabsorption
in the cortical collecting duct of the nephron.
Comparably less is known on physiologic actions of ET-3. At
low concentrations, ET-3, while significantly increasing RBF,
only moderately increases GFR [41]. Further increases of ET-3
decreases GFR and RBF, a finding that is due to RVR increase
[42]. ET-3 produces marked elevations in urine flow, free water
excretion and urinary electrolyte excretion [41, 42], findings
that partly distinguish it from ET- 1, and which are speculated to
be due to nitric oxide (NO) and prostacyclin release [13] and
only occur at low dosages [42]. This stimulation is thought to
take place through ETB-receptor stimulation [43] in glomerulus,
tubule system and collecting duct. At high doses ET-3 is
vasoconstrictive, yielding similar actions as ET- 1.
The functional differences between activation of ETA and
ET8 in different segments of the nephron are not known.
General belief links ETA to vasoconstrictive actions, although
ETB can also constrict specific vascular beds. ETB activation in
some cells, especially endothelial cells, induces release of
prostaglandins and NO. Whether ETA or ETB mediate glomer-
ular and tubular actions of ET-1 and ET-3 requires the use of
selective agonists and antagonists of ETA and ETB. With the
current knowledge we cannot link specific actions to receptor
expression.
Stimulation of ET synthesis and receptor coupling
On the basis of low plasma ET levels, which are in the range
of 1 to 5 pg/ml, it seems likely that ET isopeptides act locally in
an autocrine/paracrine way without reaching the systemic blood
circulation. ET synthesis is triggered by a variety of hormones
and peptides as well as physical forces (Table 1). The mecha-
nisms underlying ET stimulation by various agonists are as-
sumed to be transcriptional regulation [1, 44—46j. The prepro
ET-l gene contains several regulatory elements [27j. Besides
_________ Fig. 1. Suspected pathway of endothelin
synthesis. The 203 amino acids prepro ET-1 is
proteolytically cleaved by processing
endopeptidases at Lys51-Arg52 and Arg92-Arg93
to form the 39 amino acids pro ET- 1.
Endothelin-l-converting enzyme converts pro
ET- 1 to the mature ET- 1, 21 amino acids in
length, by cleaving the Trp21-Val22 bond.
Inactivation takes place either by cleavage of
Ile'9-11e2° or by receptor internalization.
functional TATA and CAAT boxes the 5' noncoding region of
the gene contains a GATA motif, necessary for promotor
function, located 130 bp upstream of the transcription start
site [47, 48], and a GATA-2 transcription factor has been cloned
from endothelial cDNA libraries, that up-regulates prepro ET- 1
transcription [49]. Within the 5' flanking region there are
binding sites for nuclear factor-i, the sequence where TGF/3 is
speculated to induce a variety of gene promotors [50]. In
addition there is an AP-l site, where protein kinase C (PKC)
acts [Si]. The promotor region of the ET gene also carries
binding sites for acute phase reactant at four positions [27]
which are thought to mediate induction of mRNA under acute
physical stress in vivo [52, 53]. It has been suggested that ET-i
elevation during acute myocardial infarction is stimulated
through these elements [54]. Other stimuli of the prepro ET- 1
gene, such as interleukins, induce gene expression through a
yet undetermined intracellular mechanism in renal endothelial
and non-endothelial cells [17, 461. Finally ET-l stimulates its
own synthesis via a mechanism distinct from those mentioned.
Autocrine positive feedback regulation through ETB receptor is
suspected [55].
Down-regulation of ET production by various stimuli is
assumed to be controlled through direct Ca2 signaling path-
ways like inosital-trisphosphate (1P3), adenylate cyclase or
guanylate cyclase [56—59] (Table 1).
Specific endothelin binding sites in the kidney
Some of the earliest studies, preceding ET receptor cloning,
localized ET receptor distribution in the kidney, without being
able to distinguish among receptor subtypes. Using 1251-ET-i
radioligand assays, ET receptors were mapped in mammalian
kidney at a very high density in the glomerular cortex region
and over the inner medulla [60]. High density of binding occurs
over the inner stripe of the outer medulla, such as the vasa recta
bundle. Proximal tubules exhibit moderate expression, whereas
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Table 1. in vitro and in vivo stimuli that alter ET synthesis
Up-regulation Down-regulation
Physical
Hormones Peptides forces Miscellaneous
Insulin Cytokines Hypoxia Heparin
Adrenalin Thrombin Shear stress ANP
Vasopressin Endotoxin Osmolarity cGMP
Angiotensin TGF-B cAMP
expressed in glomerular endothelial cells and in epithelial cells
of the thin segments of Henle's loop [631. ETA receptors are
expressed in cultured mesangial cells [8, 641. A second binding
site with equipotent affinity for the isopeptides has also been
described in mesangial cells [8, 65, 661.
Summarizing these data, ET receptor expression and ET
synthetic sites show parallel distribution in epithelial and me-
sangial as well as endothelial cells. The similar distribution
pattern of receptors and peptides suggests autocrine/paracrine
action in the glomerulus.
Fig. 2. Proposed distribution pattern of ET-1 and ET-3 synthesis
according to determination of their mRNA synthesis in rnicrodissected
rat nephrons. Symbols are: () ET-l; () ET-3; () ET-l and ET-3.
Abbreviations are: AA, afferent arteriole; EA, efferent arteriole; GLM,
glomerulus; PCT, proximal convoluted tubule; PST, proximal straight
tubule; DTL, descending thin limb of Henle's loop; ATL, ascending
thin limb of Henle's loop; MTAL, medullary thick ascending limb;
CTAL, cortical thick ascending limb; DCT, distal convoluted tubule;
CCD, cortical collecting duct; OMCD, outer medullary collecting duct;
IMCD, inner medullary collecting duct.
outer medulla shows no receptors [60, 61]. Radioligand studies
using 1251-ET-l and 1251-ET-3 together showed heterogeneity of
ET receptors in isolated mesangial cells [81. Northern blot
analysis confirmed the presence of two receptor subtypes [7] in
the kidney. However, these data did not provide information on
mRNA distribution in distinct nephron segments in order to
understand renal actions of ETs. Only recent RT-PCR assays
confirm the non-vascular localization of ET receptors in micro-
dissected kidney segments [621 (Fig. 3).
In isolated cultured cells ETa receptors are abundantly
Transmembrane signaling pathways of endothelins in the
glomerulus
Depending on the concentration, ET stimulates various ef-
fectors immediately after receptor activation (Fig. 4). The
coupling mechanism is mediated by multiple G-proteins. In
mesangial cells ET activates phospholipase C through G1 and
induces hydrolysis of phosphoinositite-bisphosphate in the
plasma membrane of mesangial cells to form (1 ,4,5)1P3 and
diacyiglycerol (DAG) [67]. (1 ,4,5)1P3 diffuses through the cy-
tosol to the endoplasmatic reticulum where it opens gated
Ca2-channeIs and activates transient Ca2-release from its
reserves [67, 68]. ET also enhances Ca2-influx through recep-
tor operated and voltage dependent Ca2-channels. Ca2-influx
accounts for the sustained increments of cytosolic Ca2 after
ET stimulation and is thought to mediate constrictive responses
to ETs. Concomitant with dephosphorylation of 1P3 an increase
of(l,3,4,5)1P4 is seen, which maybe causal for more prolonged
signal transduction responses of endothelins in glomerular
mesangial cells [67].
DAG remains within the membrane and activates PKC syn-
thesis in glomerular mesangial cells. PKC, a Ca2-dependent
kinase, whose activation is transient, leads to phosphorylation
of downstream serine/threonine kinases which are assumed to
play a crucial role in glomerular cell signaling pathways. PKC
activation results in the release of arachidonic acids which are
utilized for the synthesis of prostaglandins [691, that in turn are
responsible for regulation of diverse homeostatic physiologic
functions in the kidney, such as, vascular tone, diuresis,
natriuresis, renin secretion and are suspected to be responsible
for inflammatory events, atherogenesis, mitogenesis and onco-
genesis [70, 71].
ETs stimulate a PKC-regulated [72] phospholipase D in
mesangial cells, that hydrolizes phospholipid substrates and
induces generation of phosphatidic acids [73]. Phosphatidic
acids may serve as a lipid signal augmenting or sustaining ET
signal transduction to stimulate proliferation [73] and increase
intracellular Ca2 [741.
GLM
PCT
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Fig. 3. Proposed distribution pattern of ETA and ETB receptor mRNA
in microdissected rat nephrons. Symbols are: () ETA; () ETB; ()
ETA and ETB. Abbreviations are: AA, afferent arteriole; EA, efferent
arteriole; GLM, glomerulus; PCT, proximal convoluted tubule; PST,
proximal straight tubule; DTL, descending thin limb of Henle's loop;
ATL, ascending thin limb of Henle's loop; MTAL, medullary thick
ascending limb; CTAL, cortical thick ascending limb; DCT, distal
convoluted tubule; CCD, cortical collecting duct; OMCD, outer med-
ullary collecting duct; IMCD, inner medullary collecting duct.
ETs also induce prostaglandin synthesis in glomerular me-
sangial cells, possibly through phosphorylation of Ca2-depen-
dent phospholipase A2 (cPLA2) by PKC and p42 mitogen
activated protein (MAP)-kinase, which is likely to lead to a
sustained release of arachidonic acids in mesangial cells [38]
and prostaglandin synthesis.
ET fails to elevate intracellular cAMP when added alone to
cultured mesangial cells, however, coincubation with /3-adren-
ergic agents nearly doubles cAMP accumulation [38]. ET
through ETB receptor mediates productin of NO from L-argin-
me in the endothelium, which in turn activates guanylate
cyclase to increase cGMP. cGMP is suspected to be one of the
main antagonist to ET action and may also inhibit transcrip-
tional regulation of prepro ET- 1.
Endothelins regulate gene expression to induce long-term effects
ET triggers signaling pathways, some of which are interre-
lated, which influence transcriptional control of immediate
response genes to induce long-term changes in cell phenotype.
A variety of trans-activating factors regulate gene expression in
the nucleus. ET alters the activity of transcriptional proteins for
the AP-l family [67, 75]. However, additional trans-activating
factors may be involved and remain to be identified. ETs
stimulate mRNA levels and subsequent synthesis of c-fos,
fra-1, and c-jun proto-oncogenes in glomerular mesangial cells
[671. While the induction of c-fos is transient and is known to
cause hypertrophic changes [761, the expression for fra-1 and
c-jun, that cause hyperplastic changes, are more sustained.
Other transmembrane signaling pathways also modulate nu-
clear signaling. As already mentioned, ETs stimulate serine/
threonine kinases and thereby induce phosphorylation of trans-
activating factors. These transcription enhancers couple to
certain gene promotor regions and may enhance gene transcrip-
tion. ET1 is a potent stimulator of MAP-kinase [77]. Both MAP-
kinases have recently been postulated to mediate nuclear sig-
naling and cell growth by ETs in mesangial cells [77]. Further-
more, ETs not only stimulate serine/threonine kinases but also
ppnOSrC protein tyrosine kinase that is known to phosphorylate
tyrosine residues of target proteins [78] and together with other
tyrosine kinases is suspected to play a major role in cell growth
and cell differentiation effects. ET-l also induces the collage-
nase gene directly through transcriptional regulation of its AP-1
cis acting element [75]. It is speculative that ET-l stimulates
proteases.
Thus, in conclusion, strong evidence exists for a mitogenic
potency of the ET isopeptides in the glomerular structure,
spanning from long-term ET gene expression to direct induction
of immediate response genes that regulate a network of genes
responsible for long-term changes such as proteases and colla-
genases. However, the question remains which diseases of the
glomerulus may result from these ET-dependent signals.
Glomerular diseases related to endothelin
ETs may not only primarily induce glomerular disease, but
may also maintain or intensify glomerular dysfunction. How-
ever, until now, only assumptions concerning those pathophys-
iologic implications have been made. Those few studies, that
have been conducted have exclusively used measurements of
plasma and urine immunoreactive ET concentrations which
might not reflect the true rate of peptide generation, and that
due to the generally assumed autocrine/paracrine action of the
peptides, do not permit conclusions for tissue specific diseases.
We believe that measurement of plasma and urine immunore-
active ET are useful tools, but they are not ideal and should be
combined with molecular biologic methods. These studies
performed so far, therefore, should be examined with caution in
regards to the pathophysiologic importance of ETs (Table 2).
Post-ischemic renal failure
ETs, locally released from hypoxic renal tissue, have been
suspected to play an important role in sustained hypoperfusion
AA
GLM
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gene Fig. 4. Postulated ET signaling pathways in
expression target cells. Abbreviations are: G, G-protein;
PLA2, phospholipase A2; NO, nitric oxide;
PGs, prostaglandins; PLC, phospholipase C;
PLD, phospholipase D; AA, arachidonic
acids; PA, phosphatidic acids; 1P3, inositol-
trisphosphate, PKC, protein kinase C; DAG,
diacylglycerol; MAP-kinases, mitogen
activated kinases.
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Fig. 5. ET signaling pathways leading to matrix accumulation and proliferation in pathophysiologic conditions. Abbreviations are: G, G-protein;
NO, nitric oxide; PGs, prostaglandins; PAF, platelet activating factor; TGF-/3, transforming growth factor f3; TXA2, thromboxane A2; CsA,
Cyclosporine A.
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Table 2. Pathophysiologic conditions with altered immunoreactive
ET levels (plasma or urine)
Essential hypertension
Pulmonary hypertension
Congestive heart failure
Cardiogenic shock
Acute myocardial infarction
Cardiac trauma
Pre-eclampsia
Diabetes
Acute renal failure
Post-ischemic renal failure
Sepsis associated renal failure
End-stage renal failure (dialysis)
Chronic progressive renal failure (pre-dialysis)
—membranous proliferative glomerulonephritis
—IgA nephropathy
—minimal change nephritis
—focal glomerulonephritis
—lupus nephritis
Cyclosporin A induced nephrotoxicity
Autologous kidney transplantation (48 hr prior)
and hypofiltration in post-ischemic renal failure (Fig. 5) [36].
Glomeruli from ischemic rat kidneys produce significantly
higher amounts of plasma immunoreactive endothelin [79] that
are ameliorated after the infusion of neutralizing antibodies in
the rat kidney [36], however, ischemia does not alter renal
endothelin mRNA levels [29]. In post-ischemic renal failure the
putative role of enhanced endothelin release therefore is as-
sumed to contribute to the persistent renal vasoconstriction
beyond the period of the causal ischemic event.
In addition, during ischemia large amounts of platelet acti-
vating factor (PAF) are produced by the ischemic glomerulus
(Fig. 5), which may be due to the direct action of endothelins
[79] and may lead to subsequent events like microvascular
thrombosis. Upon platelet activation, platelet derived media-
tors such as transforming growth factor beta (TGF-13) and
thromboxane A2 (TXA2) are released, which in turn have been
shown to stimulate glomerular mesangial cells to express ET
mRNA as well as the peptide itself [16, 80].
The release of ETs is not prolonged after stimulation, but
declines after 12 to 16 hours below baseline, thus self-limiting
its effects [46]. In reality, however, post-ischemic renal failure
generally lasts longer than 12 to 16 hours, mainly due to acute
tubular necrosis. The exact role of ETs during this phase of
post-ischemic renal failure will only be clarified using ET
receptor blockade or ET synthesis inhibitors.
Sepsis associated renal failure
Renal failure, that is seen in septic and endotoxemic condi-
tions may be caused by excess cytokine liberation from acti-
vated cells. Tumor necrosis factor a (TNF-a) increases ET-1
release and ET- 1 mRNA content in glomerular capillary endo-
thelial cells (Fig. 5) [48] and epithelial cells [17]. Data on ET
generation in response to interleukin IL-113 are not as consis-
tent. It has no stimulatory effect on glomerular mesangial cells
[16] but stimulates ET-1 release from renal epithelial cells [17].
The activation of ET by endotoxin has been shown in vivo (Fig.
5) [81—84]. In addition, early investigations of endotoxin-asso-
ciated renal failure showed evidence for an ET-mediated,
profound decrease in GFR. In humans so far, circulating ET
concentrations have been shown to be elevated in septic
conditions [85]. The potential reasons for elevation are manifold
(direct effects of lipopolysaccharides, activation of PAF, TXA2,
TGF-J3, sepsis-associated congestive heart failure, direct pul-
monal liberation, etc.), but do not provide striking evidence for
its contribution to septic renal failure.
Cyclosporin A induced nephrotoxicity
Cyclosporin A induces renal vasoconstnction and glomerular
dysfunction with increases in RVR and decreases in GFR and
RBF [86, 87] and eventually severe hypertension. In cultured
human endothelial cells the drug stimulates production of ET
[88]. Cyclosporin A administration in rats increased plasma ET
levels due to the direct action of cyclosporin A on the endothe-
hum (Fig. 5) [87]. The infusion of neutralizing antibodies
reduced the effects of cyclosporin on the rat kidney [87]. It is,
however, not concluded yet if endothehins are cauasal or
secondary in cyclosporin A induced nephrotoxicity. Long-term
renal changes due to cyclosporin A include scarring and ele-
vated collagen mRNA levels; these changes might be related to
ET actions [89].
Chronic progressive renal failure (pre-dialysis)
Whereas the pathophysiological states outlined above may be
induced by short-term ET effects, other disease entities, that
are suspected to be due to the peptide's actions, include matrix
changes and glomeruloscierosis (scarring). These pathologic
changes implicate proliferative cell growth as well as basement
membrane remodeling. In ablation of renal mass in rats, ET
mediates glomerular structural abnormalities and is significantly
correlated with development of focal glomerulosclerosis, imply-
ing association between renal disease progression and renal
ET-1 gene expression as well as ET-1 urinary excretion [90].
Human data are based solely on urine and plasma immunore-
active ET measurements and present conflicting results [91].
Changes in renal configuration, possibly leading to chronic
progressive renal failure, may be due to several mechanisms
(Fig. 5). The collagenase gene has been demonstrated to be
stimulated by ET- 1 directly [75] whereas matrix accumulation
in the glomerular mesangial structure is a complex event and
associated with the accumulation of cohlagens (I, III, IV, V),
laminin, proteoglycans, complement and immunoglobulins [92,
93]. Glomerular epithelial and endothehial cells are assumed to
be the main sources of proteoglycans [94], and cultured mesan-
gial cells have been shown to produce collagens [95]. Pheno-
typic changes in the glomerular mesangial structure through
increased transcription and translation of these matrix proteins
by ETs, however, are lacking. ETs act more likely through their
mitogenic properties, their ability as a co-mitogen for growth
factors, or their direct proliferative effect on mesangial cells.
In this review we have stressed the important cellular signal-
ing pathways and cellular actions triggered by ETs. In addition
we have emphasized both acute vasoconstrictor (that is, hemo-
dynamic) renal responses, and more chronic mitogenic and
matrix-related mesangial responses to ETs. Although growing
evidence exists for the role of endothelins in renal pathophys-
iologic conditions, progress will only be achieved by the avail-
ability of ET receptor blockers and endothelin synthesis inhib-
itors. As soon as these drugs become clinically available further
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clarification of functional renal deterioration and disease due to
El will be possible.
Acknowledgments
This work was supported by the NIH grants HL 22563 and DK 41684
to Michael J. Dunn.
Dr. Marsen is a recipient of a research fellowship from the Deutsche
Forschungsgemeinschaft and Dr. Schramek is a recipient of a research
fellowship from the Max Kade Foundation.
The authors want to thank Michael S. Simonson for critical review of
the manuscript as well as for sharing unpublished data and recently
submitted publications.
Reprint requests to Michael J. Dunn, M.D., Department of Medi-
cine, University Hospitals of Cleveland, 2074 Abington Road, Cleve-
land, Ohio 44106,
References
1. YANAGISAWA MN, KURIHARA H, KIMua S. TOMOBE Y, Koa-
YASHI M, MITSUI Y, YAZAIU Y, GoTo K, MASAKI T: A novel
potent vasoconstrictor petide produced by vascular endothelial
cells, Nature 322:411—415, 1988
2. IN0UE A, YANAGISAWA M, KIMua. S. KASUYA Y, MIYAucHI T,
GoTo K, MASAKI T: The human endothelin family: Three structur-
ally and pharmacologically distinct isopeptides predicted by three
separate genes. Proc Nat! Acad Sci USA 86:2863—2867, 1989
3. AHN K, BENINGO K, OLDS G, HuoE D: The endothelin-converting
enzyme from human umbilical vein is a membrane-bound metallo-
protease similar to that from bovine aortic endothelial cells. Proc
Nail Acad Sd USA 89:8606—8610, 1992
4. ORNAKA K, TAKAYANAGI R, YAMAUCHI T, OKAzAKI H, OHASFI!
M, UMEDA F, NAWATA H: Identification and characterization of
endothelin converting activity in cultured bovine endothelial cells.
Biochem Biophys Res Commun 168:1128—1136, 1990
5. OKADA K, MIYAZAKI Y, TAKADA J, MATSUJAMA K, YAMAIU T,
YANO M: Conversion of big endothelin-1 by membrane-bound
metalloendopeptidase in cultured bovine endothelial cells, Biochem
Biophys Res Commun 171:1192—1198, 1990
6. ARAI H, Saut H, ARAMOIFI I, OHKUBO H, NAKANISHI S: Cloning
and expression of a cDNA encoding an endothelin receptor. Nature
348:730—732, 1990
7. SAKURAI T, YANAGISAWA M, TOKUWA Y, MIYAZAKI H, KIMuI
5, GoTo K, MASAKI T: Cloning of a eDNA encoding a non-
isopeptide selective subtype of the endothelin receptor. Nature
348:732—735, 1990
8. MARTIN ER, BRENNER BM, BALLERMANN BJ: Heterogneity of cell
surface endothelin receptors. J Biol Chem 265:14044-14049, 1990
9. Lu.i H-Y, KAJI EH, WINKEL OK, IvES HE, LODISH HF: Cloning
and functional expression of a vascular smooth muscle endothelin- I
receptor. Proc Nail Acad Sci USA 88:3185—3189, 1998
10. JACKMAN HL, TAN F, TAME! H, BEURLING-HARBURY C, Li X-Y,
SKIDGEL RA, EaonOs EG: A peptidase in human platelets that
deamidates Tachykinins. J Rio! Chem 265:11265—11272, 1990
11. JACKMAN HL, MORRIS PW, RABITO SF, JOHANSSON GB, ERDOS
EG: Inactivation of endothelin-l by an enzyme of the vascular
endothelial cells. (abstract) Hypertension 20:425, 1992
12. JENGAY, MARTIN LL, BALWIERCZAK JL, DENG Y: Purification of
a soluble endothelin degradation enzyme from rat kidney. (abstract)
3rd Endothelin Meeting, Houston, 1993, p 52
13. DENUCCI G, THOMAS R, D'ORLEANS-JUSTE P, AUTUNES E,
WALDER C, WARNER TD, VANE Ja: Pressor effects of the circulat-
ing endothelin are limited by its removal in the pulmonary circula-
tion and by the release of prostacyclin and endotheium-derived
relaxing factor. Proc Nat! Acad Sci USA 85:9797—9800, 1988
14. MARSDEN PA, DORFMAN DM, COLLINS T, BRENNER BM, O1UUN
SH, BALLERMANN BJ: Regulated expression of endothelin 1 in
glomerular capillary endothelial cells. Am J Physiol 26l:Fl 17—
F125, 1991
15. SAKAMOTO H, SASAKI S, HIRATA Y, IMAI T, ANDO K, IDA T,
SAKURAI T, YANAGISAWA M, MASAKI T, MARUMO F: Production
of endothelin-l by rat cultured mesangial cells. Biochem Biophys
Res Commun 169:462—468, 1990
16. ZOJA C, Oaisio S, PERIc0 N, BENIGNI A, MORIGI M, BENATrI L,
RAMBALDI A, REMUZZI G: Constitutive expression of endothelin
gene in cultured human mesangial cells and its modulation by
transforming growth factor-13, thrombin, and a thromboxane A2
analogue. Lab Invest 64:16—20, 1991
17. OHTA K, HIRATA Y, IMAI T, KANNO K, EMORI T, SHICHIRI M,
MARUMO F: Cytokine-induced release of endothelin-l from porcine
renal epithelial cell line. Biochem Biophys Res Commun 169:578—
584, 1990
18. CYBULSKY AV, STEWART DJ, CYBULSKY MI: Glomerular epithelial
cells produce endothelin-l. Am J Soc Nephrol 3:1398-1404, 1993
19. KOSAKA T, SUZUKI N, MATSUMOTO H, IroN Y, YASUHARA T,
ONDA H, FUJINO M: Synthesis of the vasoconstrictor peptide
endothelin in the kidney. FEBS Lett 249:42—46, 1989
20. KOHAN DE: Endothelin synthesis by rat tubule cells. Am J Physiol
26l:F22l—F226, 1991
21. BLOCH KD, HoNG CC, EDDY RL, SHOWS TB, QUERTERMOUS T:
cDNA cloning and chromosomal assignment of the endothelin 2
gene: Vasoactive intestinal contractor peptide is rat endothelin 2.
Genomics 10:236—242, 1991
22. BLOCH KD, EDDY RL, SHOWS TB, QUERTERMOUS T: cDNA
cloning and chromosomal assignment of the gene encoding endo-
thelin 3. JBiol Chem 264:18156—18161, 1989
23. MCCUMBER MW, Ross CA, GLASER BM, SNYDER SH: Endothelin:
Visualization of mRNAs by in situ hybridization provides evidence
for local action. Proc Nat! Acad Sci USA 86:7285—7289, 1989
24. YANAGISAWA M, INOUE A, ISHIKAWA T, KASUYA Y, KIMURA S,
KUMAGAYE S-I, NAKAJIMA K, WATANABE TX, SAKAKIBARA 5,
GoTo K, MASAKI T: Primary structure, synthesis and biological
activity of rat endothelin, an endothelium-derived vasoconstrictor
peptide. Proc Nat! Acad Sci USA 85:6964—6967, 1988
25. MCCUMBER MW, Ross CA, SNYDER SH: Endothelin in brain:
Receptors, mitogenesis, and biosynthesis in glial cells. Proc Nat!
Acad Sci USA 87:2359—2363, 1990
26. YOSHIZAWA T, SHINMI 0, GIAID A, YANAGISAWA M, GIBSON SJ,
KIMURA S, IJCHIYAMA Y, POLAK JM, MASAKI T, KANAZAWA I:
Endothelin: A novel peptide in the posterior pituitary system.
Science 247:462—464, 1990
27. IN0UE A, YANAGISAWA M, TAKUWA Y, MITsuI Y, KOBAYASHI M,
MASAKI T: The human preproendothelin gene. J Riot Chem 264:
14954—14959, 1989
28. SAIDA K, MISUI Y, ISHIDA N: A novel peptide, vasoactive intes-
tinal constrictor, of a new (endothelin) peptide family. J Biol Chem
264:14613—14616, 1989
29. FIRTH JD, RATCLIFFE PJ: Organ distribution of the three rat
endothelin messanger RNAs and the effect of ischemia on renal
gene expression. J Gun Invest 90:1023—1031, 1992
30. UCHIDA S, TAKEMOTOF, OGATA E, KUROKAWA K: Detection of
endothelin-1 mRNA by RT-PCR in isolated rat renal tissues.
Biochem Biophys Res Commun 188:108—113, 1992
31. UJIIE K, TERADA Y, NONOGUSHI H, SHINOHARA M, TOMITA K,
MARUM0 F: Messanger RNA expression and synthesis of endothe-
lin-l along rat nephron segments. J C!in Invest 90:1043—1048, 1992
32. NUNEZ DiR, BROWN Mi, DAVENPORT AP, NEYLON CB, SCHO-
FIELD JP, WYSE RK: Endothelin 1 mRNA is widely expressed in
porcine and human tissues. J Clin Invest 85:1537—1541, 1990
33. OHKUBO S. 001 K, HOSOYA M, MATSUMOTO H, SUZUKI N,
KIMURA C, OND0 H, FUJINO M: Specific expression of human
endothelin-2 (ET-2) gene in a renal adenocarcinoma cell line.
Molecular cloning of eDNA encoding the precursor of ET-2 and its
characterization. FEBS Lett 274:136—140, 1990
34. Deleted in proof
35. HIRATA Y, MATSUOKA H, KIMURA K, FUKUI K, HAYAKAWA H,
SUZUKI E, SUGIMOTO T, SuGIMOT0 T, YANAGISAWA M, MASAKI
T: Renal vasoconstriction by the endothelial cell-derived peptide
endothelin in spontaneously hypertensive rats. Circ Res 65:1370—
1379, 1989
36. K0N V, YOSHIOKA T, Foco A, ICHIKAWA I: Glomerular actions of
endothelin in vivo. J Gun lnvest 83:1762—1767, 1989
37. KATOH T, CHANG H, UCHIDA S, OKUDA T, KUROKAWA K: Direct
Marsen e al: Renal actions of endothelin in disease 343
effects of endothelin in the rat kidney. Am J Physiol 258:F397—
F402, 1990
38. SIM0N5ON MS, DUNN MJ: Endothelin-1 stimulates contraction of
rat glomerular mesangial cells and potentiates f3-adrenergic-medi-
ated cyclic adenosine monophosphate accumulation. J Clin Invest
85:790—797, 1990
39. BADR KF, Muiuv JJ, BREYER MD, TAKAHASHI K, INAGAMI T,
HARRIS RC: Mesangial cell, glomerular and renal vascular re-
sponses to endothelin in the rat kidney. J Clin Invest 83:336—342,
1989
40. G0ETZ KL, WANG BC, MADURED JB, ZHU JL, LEADLEY RL JR:
Cardiovascular, renal and endocrine responses to intravenous
endothelin in conscious dogs. Am J Physiol 255:R1064—R1068, 1988
41. YAMASHITA Y, YUKIMURA T, MIuR& K OKUMURA M, YAMAMOTO
K: Effects of endothelin-3 on renal functions. J Pharmacol Exp
Ther 259: 1256-1260, 1991
42. STIER CT JR, QUILLEY CP, McGIFi' JC: Endothelin-3 effects on
renal function and prostanoid release in the rat isolated kidney. J
Pharmacol Exp Ther 262:252—256, 1992
43. TAKAYANAGI R, KITAZUMI K, TAKASAKI C, OHNAKA K, AIMOTO
S, TASAKA K, OHASHI M, NAWATA H: Presence of non-selective
type of endothelin receptor on vascular endothelium and its linkage
to vasdilation. FEBS Lett 282:103—106, 1991
44. HORIE M, UCHIDA S, YANAGISAWA M, MATSUSHITA Y,
KUROKAWA K, OGATA E: Mechanisms of endothelin-1 mRNA and
peptides induction by TGF-/3 and TPA in MDCK cells. J Cardio-
vasc Pharmaco! 17:S222—S225, 1991
45. KURIHARA H, Y0sHIzUMI M, SUGUYAMA T, TAKAKU F, YANA-
GISAWA M, MASAKI T, HAMAOKI M, KATO H, YAZAKI Y: Trans-
forming growth factor-13 stimulates the expression of endothelin
mRNA by vascular endothelial cells. Biochem Biophys Res Corn-
mun 159:1435—1440, 1989
46. MARSDEN PA, BRENNER BM: Transcriptional regulation of the
endothelin-1 gene by TNF-a. Am J Physiol 262:C854—C86l, 1992
47. WILSON D, DORFMAN DM, ORKIN SB: A nonerythroid GATA-
binding protein is required for function of the human preproendo-
thelin-1 promotor in endothelial cells. Mo! Cell Biol 10:4854—4862,
1990
48. LEE ME, TEMIZER DH, CLIFFORD JA, QUERTERMOUS T: Cloning
of GATA-binding protein that regulates endothelin-1 gene expres-
sion in endothelial cells. J Biol Chem 266:16188—16192, 1991
49. DORFMAN DM, WILSON DB, BRUNS G, ORKIN SB: Human tran-
scription factor GATA-2. J Biol Chem 267:1279—1285, 1992
50. Ross P, KARSENTY G, ROBERTS AB, ROCHE NS, Spoiu. MB,
DECROMBRUGGHE B: A nuclear factor 1 binding site mediates the
transcriptional activation of a type I collagen promotor by trans-
forming growth factor-a. Cell 52:405—414, 1988
51. YANAGISAWA M, INouE A, TAKUWA Y, MITSUI Y, KOBAYASHI M,
MASAKI T: The human preproendothelin-1 gene: Possible regula-
tion by endothelial phosphoinosite turnover signaling. J Cardiovasc
Pharmacol 13:S13—S17, 1989
52. FOWLKES DM, MULLIS NT, COMEAU CM, CRABTREE OR: Poten-
tial basis for regulation of the coordinately expressed fibrinogen
genes: Homology in the 5' flanking regions. Proc Nat! Acad Sci
USA 81:2313—2316, 1984
53. ADRIAN OS, KORINEK BW, BOWMAN BH, YANG F: The human
transferrin gene: 5' region contains coserved sequences which
match the control elements regulated by heavy metals, glucocorti-
coids and acute phase reaction. Gene 49:167—175, 1986
54. MIYAUCHI T, YANAGISAWA M, TOMIZAWA T, SUGISHITA Y,
SUZUKI N, FUJINO M, AJISAKA R, GOTO K, MASAKI T: Increased
plasma concentrations of endothelin- 1 and big endothelin- 1 in acute
myocardial infarction. Lancet ii8653:53—54, 1989
55. SAUONMAA 0, NYMAN T, FYHRQUIST F: Endothelin-l stimulates
its own synthesis in human endothelial cells. Biochem Biophys Res
Commun 188:286—291, 1992
56. YOKOKAWA K, MANDAL AK, KOHNO M, HORIO T, MURAKAWA
K-I, YASUNARI K, TAKEDA T: Heparin suppresses endothelin-l
action and production in spontanously hypertensive rats. Am J
Physio! 32:Rl035—R1041, 1992
57. KOHNO M, YASUNARI K, YOKOKAWA K, MURAKAWA K, HORIO T,
TAKEDA T: Inhibition by atrial and brain natriuretic peptides on
endothelin-1 secretion after stimulation with angiotensin II and
thrombin of cultured human endothelial cells. J Clin Invest 87:
1999—2004, 1991
58. SAIJONMAA 0, RisriAu A, FYHRQUIST F: Atrial natriuretic
peptide, nitroglycerine, and nitroprusside reduce basal and stimu-
lated endothelin production fron cultured endothelial cells. Bio-
chern Biophys Res Commun 173:514—520, 1990
59. HU RM, LEVIN ER, PEDRAM A, FRANK HJL: Atrial natriuretic
petide inhibits the production and secretion of endothelin from
cultured endothelial cells. J Biol Chem 24:17384-17389, 1992
60. KOHZUKI M, JOHNSTON CI, CHAt SY, CASLEY Di, MENDELSOHN
FAO: Localization of endothelin-receptors in rat kidney. Eur J
Pharmacol 160:193—194, 1989
61. JONES CR, HILEY CR, PELTON JT, MILLER RC: Audioradiographic
localization of endothelin binding sites in the kidney. Eur J Phar-
macol 163:379—382, 1989
62. TERADA Y, TOMITA K, NONAGUSHI H, MARUMO F: Different
localization of two types of endothelin receptor mRNA in micro-
dissected rat nephron segments using reverse transcriptase and
polymerase chain reaction assay. J Clin Invest 90:107—112, 1992
63. H0RI 5, KOMATSU Y, SHIGEM0TO R, MIzUN0 N, NAKANISHI S:
Distinct tissue ditribution and cellular localization of two mes-
sanger ribonucleic acids encoding different subtypes of rat endo-
thelin receptors. Endocrinology 130:1885—1895, 1992
64. TAKEDA M, BREYER MD, NOLAND TD, HOMMA T, HOOVER RL,
INAGAMI T, KON V: Endothelin-1 receptor antagonist: Effects on
endothelin- and cyclosporine-treated mesangial cells. Kidney Int
41:1713—1719, 1992
65. SUGIURA M SNADJAR RM, SCHWARTZBERG M, BADR KF, INA-
GAMI T: Identification of two types of specific endothelin receptors
in rat mesangial cell. Biochem Biophys Res Comrnun 169:1396—
1401, 1989
66. BALDI E, DUNN Mi: Endothelin binding and receptor down regu-
lation in rat glomerular mesangial cells. J Pharrnacol Exp Ther
256:581—586, 1991
67. SIM0NS0N MS, WANN 5, MENE P, DUBYAK GR, KESTER M,
NAKAZATO Y, SEDOR JR, DUNN Mi: Endothelin stimulates phos-
pholipase C, Na/K exchange, c-fos expression and mitogenesis
in rat mesangial cells. J Clin Invest 83:708—712, 1989
68. SIMONSON MS, DUNN Mi: Ca2 signaling by distinct endothelin
peptides in glomerular mesangial cells. Exp Cell Res 192:148-156,
1991
69. SIMONSON MS, WOLFE iA, KONIECZKOWSKI M, SEDOR JR, DUNN
MJ: Regulation of prostaglandin endoperoxide synthase gene ex-
pression in cultured rat mesangial cell: Induction by serum via
protein kinase-C-dependent mechanism. Molec Endocrin 3:441—
451, 1991
70. SMITH WL: The eicosanoids and their biochemical mechanism of
action. Biochem J 259:315—324, 1989
71. POMERANTZ KB, HAJJAR DP: Eicosanoids in regulation of smooth
muscle cell phenotype, proliferative capacity, and cholesterol me-
tabolism. Arteriosclerosis 9:413—429, 1989
73. MARTIN TW, FELDMAN DR, GOLDSTEIN KE, WAGNER JR Long-
term phorbol ester treatment dissociates phospholipase D activa-
tion from phosphoinositide hydrolysis and prostaglandin synthesis.
Biochem Biophys Res Commun 165:319-326, 1989
74. KESTER M, THOMAS CP, WANG J, DUNN Mi: Platelet-activating
factor stimulates multiple signaling pathways in cultured rat mesan-
gial cells. J Cell Phys 153:244—255, 1992
75. MOOLENAR WH, KRUIGER W, TILLY BC, VERLAAN I, BIERMAN
AJ, DELAAT SA: Growth factor-like action of PA. Nature 323:171—
173, 1986
76. SIMONSON MS, JONES JM, DUNN Mi: Differential regulation of fos
andjun gene expression and AP-1 cis element activity by endothe-
un isopeptides: Possible Implications for mitogenic signaling by
endothelin. J Biol Chern 267:8643—8649, 1992
77. ITo H, HIRATA Y, HIR0E M, T5UJINO M, ADACHI 5, TAKAMOTO T,
NI'I-FA M, TANIGUSHI K, MARUMO F: Endothelin-l induces hyper-
trophy with enhanced expression of muscle-specific genes in cul-
tured neonatal rat cardiomyocytes. Circ Res 69:209—215, 1991
78. WANG Y, SIMONSON MS. P0UYSSEGUR i, DUNN Mi: Endothelin
rapidly stimulates mitogen-activated protein kinase activity in rat
mesangial cells. Biochem J 287:589—594, 1992
344 Marsen et a!: Renal actions of endothelin in disease
79. SIMONSON MS, HERMAN WH: Protein kinase C and protein ty-
rosine kinase activity contribute to mitogenic signaling by endothe-
un-i. J Biol C/tern (in press)
80. LOPZ-FARRE A, GOMEZ-GARRE D, BERNABEU F, Lopz-NovoA
JM: A role for endothelin in the maintainance of post-ischemic
renal failure in the rat. J Physiol 444:513—522, 1991
81. OHLSTEIN EH, STORER BL, BUTCHER JA, DEBOUCK C, FEUER-
STEIN G: Platelets stimulate expression of endothelin mRNA and
endothelin biosynthesis in cultured endothelial cells. Circ Res
69:832—841, 1991
82. SuGIua M, INAGAMI T, KON V: Endotoxin stimulates endothelin-
release in vivo and in vitro as determined by radioimmunoassay.
Biochem Biophys Res Comrnun 161:1220—1227, 1989
83. PERNOW J HEMSEN A, LUNDBERG JM: Increased plasma levels of
endothelin-like immunoreactivity during endotoxin administration
in the pig. Acta Physiol Scand 137:317—318, 1989
84. MOREL DR, LACROIX iS, HEMSEN A, STEINIG DA, PITTET i-F,
LUNDBERG iM: Increased plasma and pulmonary lymph levels of
endothelin during endotoxin shock. Eur J Pharmacol 167:427—428,
1989
85, NAKAMURA T, KASAI K, SEKIGUSHI Y, BANBA N, TAKAHASHI E,
EMOTO T, HArFORI Y, SHIMODA S-I: Elevation of plasma endo-
thelin concentrations during endotoxin shock in dogs. Eur J P/tar-
macol 205:277—282, 1991
86. WEITZBERG E, LUNDBURG JM, RUDEHILL A: Elevated plasma
levels of endothelin in patients with sepsis syndrome. Circ Shock
33:222—227, 1991
87. CURTIS JJ, LUKE RG, DuBovsKY E, DIETHELM AG, WELCHEL JD,
JONES P: Cyclosporine-A in therapeutic doses increases renal
allograft vascular resistance. Lancet ii 8505:477—479, 1986
88. K0N V, SucuuRA M, INAGAMI T, HARVIE BR, ICHIKAWA I,
HOOVER RL: Role of endothelin in cyclosporine-induced glomeru-
lar dysfunction. Kidney mt 37:1487—1491, 1990
89. BUNCHMAN TE, BROOKSHIRE CA: Cyclosporine-induced synthesis
of endothelin by cultured human endothelial cells. J C/in Invest
88:310—314, 1991
90. NAST CC, ADLER SG, ARTISHEVSKY A, KRESSER CT, AHMED K,
ANDERSON PS: Cyclosporine induces elevated procollagen alpha 1
mRNA levels in the rat cortex. Kidney mt 39:631—638, 1991
91. ORislo S, BENIGN! A, BRIZZI I, CORNA D, PERIc0 N, Z0JA C,
BENATrI L, REMUZZI 0: Renal endothelin gene expression is
increased in remnant kidney and correlates with disease progres-
sion. Kidney mt 43:354—358, 1993
92. OHTA K, HIRATA Y, SHICHIRI M, KANNO K, EM0RI T, TOMITA K,
MARUMO F: Urinary excretion of endothelin-l in normal subjects
and patients with renal disease. Kidney mt 39:307—3 11, 1991
93. FUNABIKI KJ, H0RIK0SHI 5, TOMINO Y, NAGAI Y, KOIDE H:
Immunohistochemical analysis of extracellular components in the
glomerular sclerosis of patients with glomerulonephritis. Clin
Nephrol 34:239—246, 1990
94. Yosio K, TAKEMURA T, TORDA M, AKANO N, MIYAMOTO H,
OOSHIMA A, MAKI S: Glomerular localization of type III collagen in
human kidney disease. Kidney mt 35:1203—1211, 1989
95. STOW JL, SOROKA CJ, MACKAY K, STRIKER L, SRIKER G,
FARQUHAR MG: Basement membrane heparane sulfate proteogly-
can is the main proteoglycan synthesized by glomerular epithelial
cells in culture. Am J Pathol 135:637—646, 1989
96. OHYAMA K, SEYER JM, RAGHOW R, KANG AH: Extracellular
matrix phenotype of rat mesangial cells in culture. Biosynthesis of
collagen types I, III, IV, and V and a low molecular weight
collagenous component and their regulation by dexamethasone. J
Lab Clin Med 116:219—227, 1990
